These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 18398027

  • 1. Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo.
    Kendall A, Anderson H, Dunbier AK, Mackay A, Dexter T, Urruticoechea A, Harper-Wynne C, Dowsett M.
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):855-63. PubMed ID: 18398027
    [Abstract] [Full Text] [Related]

  • 2. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
    Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM.
    J Clin Oncol; 2009 Mar 20; 27(9):1382-7. PubMed ID: 19224856
    [Abstract] [Full Text] [Related]

  • 3. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
    Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, Simonsen M, Metheny T, Petroff BK.
    Breast Cancer Res Treat; 2007 Nov 20; 106(1):75-84. PubMed ID: 17221152
    [Abstract] [Full Text] [Related]

  • 4. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
    Harper-Wynne C, Ross G, Sacks N, Salter J, Nasiri N, Iqbal J, A'Hern R, Dowsett M.
    Cancer Epidemiol Biomarkers Prev; 2002 Jul 20; 11(7):614-21. PubMed ID: 12101108
    [Abstract] [Full Text] [Related]

  • 5. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
    Acta Oncol; 2009 Jul 20; 48(4):522-31. PubMed ID: 19173092
    [Abstract] [Full Text] [Related]

  • 6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
    J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550
    [Abstract] [Full Text] [Related]

  • 7. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
    Geisler J, Helle H, Ekse D, Duong NK, Evans DB, Nordbø Y, Aas T, Lønning PE.
    Clin Cancer Res; 2008 Oct 01; 14(19):6330-5. PubMed ID: 18829517
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.
    J Clin Oncol; 2009 Jun 01; 27(16):2630-7. PubMed ID: 19380449
    [Abstract] [Full Text] [Related]

  • 10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Jun 01; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 11. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
    Kendall A, Dowsett M.
    Endocr Relat Cancer; 2006 Sep 01; 13(3):827-37. PubMed ID: 16954432
    [Abstract] [Full Text] [Related]

  • 12. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
    Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, Hamer P, Brown-Shimer S, Pierce K, Gaur V, Carney W.
    J Clin Oncol; 2008 Jun 01; 26(16):2653-8. PubMed ID: 18443351
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
    Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A.
    Clin Cancer Res; 2008 May 01; 14(9):2673-80. PubMed ID: 18451231
    [Abstract] [Full Text] [Related]

  • 14. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM.
    Adv Ther; 2008 Dec 01; 25(12):1257-75. PubMed ID: 19096768
    [Abstract] [Full Text] [Related]

  • 15. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole.
    Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM.
    Pharmacogenomics J; 2012 Feb 01; 12(1):10-21. PubMed ID: 20697427
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
    Chow LW, Yip AY, Loo WT, Toi M.
    Cancer Lett; 2008 Apr 18; 262(2):232-8. PubMed ID: 18248884
    [Abstract] [Full Text] [Related]

  • 17. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
    Mousa NA, Crystal P, Wolfman WL, Bedaiwy MA, Casper RF.
    Menopause; 2008 Apr 18; 15(5):875-84. PubMed ID: 18480735
    [Abstract] [Full Text] [Related]

  • 18. Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment?
    Nordman IC, Dalley DN.
    Breast J; 2008 Apr 18; 14(6):562-9. PubMed ID: 19000052
    [Abstract] [Full Text] [Related]

  • 19. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
    Goss PE.
    Breast Cancer Res Treat; 2008 Dec 18; 112 Suppl 1():45-52. PubMed ID: 18785006
    [Abstract] [Full Text] [Related]

  • 20. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May 18; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.